Millioni Chhabra, a scientist working on finding cure for HIV in North Carolina USA

Investors

Our investor proposition

GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.

Second quarter 2018 results and R&D update

Emma Walmsley, Simon Dingemans and Hal Barron

On Wednesday 25 July we will announce our second quarter 2018 results for the period ended 30 June 2018 and give an update on R&D.

Find out more

Following the announcement there will be a webcast, hosted by Emma Walmsley, CEO, Simon Dingemans, CFO, and Hal Barron, Chief Scientific Officer and President, R&D at 14:15 BST, 09:15 EDT.

Register for the webcast

Latest information

GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

On Tuesday 27 March, we announced that GSK has reached an agreement with Novartis to buyout Novartis’s 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).

The press release is available here and materials from a call for investors and analysts are available below.